Hazel Hunt
Chief Tech/Sci/R&D Officer at CORCEPT THERAPEUTICS INCORPORATED
Net worth: 2 M $ as of 30/03/2024
Profile
Hazel Hunt is currently the Chief Scientific Officer at Corcept Therapeutics, Inc. She previously worked as the Operations Director at Pulmagen Therapeutics (Synergy) Ltd.
and as the Director-Chemistry & Operations at Argenta Bank en Verzekeringsgroep NV.
Hazel also held positions as a Principal at the University of Oxford and the University of California, Davis, as well as a Senior Chemist at Glaxo Group Research Ltd.
She completed her undergraduate degree at the Australian National University and obtained a doctorate from the University of Southampton.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 08/02/2024 | 93,354 ( 0.09% ) | 2 M $ | 30/03/2024 |
Hazel Hunt active positions
| Companies | Position | Start |
|---|---|---|
| CORCEPT THERAPEUTICS INCORPORATED | Chief Tech/Sci/R&D Officer | 31/12/2010 |
Former positions of Hazel Hunt
| Companies | Position | End |
|---|---|---|
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Chief Operating Officer | 31/12/2010 |
Argenta Bank en Verzekeringsgroep NV
 Argenta Bank en Verzekeringsgroep NV Major BanksFinance Argenta Bank en Verzekeringsgroep NV is a customer-centric bank that prioritizes the needs of its clients. Argenta Bank en Verzekeringsgroep is based in Antwerp, BE, and has subsidiaries in Belgium, Germany, Luxembourg, and the Netherlands. The Belgian company aims to make banking easy for its customers, and this is reflected in its approach to business. The private company was founded in 1956 by Karel van Rompuy, and Peter Devlies has been the CEO of the company since 2023. | Corporate Officer/Principal | 31/12/2010 |
| Glaxo Group Research Ltd. | Corporate Officer/Principal | - |
| University of California, Davis | Corporate Officer/Principal | - |
| University of Oxford | Corporate Officer/Principal | - |
Training of Hazel Hunt
| Australian National University | Undergraduate Degree |
| The University of Southampton | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CORCEPT THERAPEUTICS INCORPORATED | Health Technology |
| Private companies | 3 |
|---|---|
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
Argenta Bank en Verzekeringsgroep NV
Argenta Bank en Verzekeringsgroep NV Major BanksFinance Argenta Bank en Verzekeringsgroep NV is a customer-centric bank that prioritizes the needs of its clients. Argenta Bank en Verzekeringsgroep is based in Antwerp, BE, and has subsidiaries in Belgium, Germany, Luxembourg, and the Netherlands. The Belgian company aims to make banking easy for its customers, and this is reflected in its approach to business. The private company was founded in 1956 by Karel van Rompuy, and Peter Devlies has been the CEO of the company since 2023. | Finance |
| Glaxo Group Research Ltd. |
- Stock Market
- Insiders
- Hazel Hunt
